←
Miller Lab Group42 posts
Miller Lab Group avatar

Miller Lab Group

@WRMillerLab

Research focused on understanding and combating antibiotic resistance.

◷ Joined October 2022▧ 7 Photos and videos
Miller Lab Group avatar
Miller Lab Group@WRMillerLab·12 Jul 2024

While population analysis profile, the gold-standard for detecting heteroresistance, is not feasible for the clinical lab, we found correlations between heteroresistance and disk diffusion diameter that could be explored as a useful screening test.

Post attachment
Miller Lab Group avatar
Miller Lab Group@WRMillerLab·12 Jul 2024

Heteroresistant strains also displayed a shift in the population distribution of MICs after cefiderocol exposure. Using whole genome sequencing we found that isolates with non-susceptible MICs developed mutations in the fptA gene encoding the pyochelin receptor, among others.

Post attachment
Miller Lab Group avatar
Miller Lab Group@WRMillerLab·12 Jul 2024

Importantly, we also show that the heteroresistant phenotype persists when controlling for inoculum (top panel) and when using iron depleted Muller Hinton broth (bottom panel).

Post attachment
Miller Lab Group avatar
Miller Lab Group@WRMillerLab·12 Jul 2024

6 of 12 isolates with a frameshift mutation in the pirR response regulator gene were found to be resistant or heteroresistant, while none of the 6 control strains with wild type TBDRs displayed this phenotype.

Miller Lab Group avatar
Miller Lab Group@WRMillerLab·12 Jul 2024

We used a collection of 498 Pseudomonas isolates from the US and South America collected before the introduction of cefiderocol. We found that mutations in these genes were present in between 5-30% of isolates.

Miller Lab Group avatar
Miller Lab Group@WRMillerLab·12 Jul 2024

Cefiderocol, a siderophore cephalosporin, uses TonB dependent receptors (TBDRs) for drug uptake. In Pseudomonas, the catechol receptors PirA and PiuA (whose expression is controlled by PirRS) play a major role.

Post attachment
Miller Lab Group avatar
Miller Lab Group@WRMillerLab·12 Jul 2024

Cefiderocol retains in vitro susceptibility against many MDR-pathogens, including Pseudomonas aeruginosa. In this work, we examined cefiderocol heteroresistance, or the presence of a subpopulation of resistant organisms in an otherwise susceptible background.

Miller Lab Group avatar
Miller Lab Group@WRMillerLab·12 Jul 2024

Now out from our lab in #AACJournal Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin | Antimicrobial Agents and Chemotherapy journals.asm.org/doi/10.1128…

Miller Lab Group avatar
Miller Lab Group@WRMillerLab·7 Apr 2024

In vivo, constitutive activation of MadRS led to larger cardiac microlesions in a mouse peritonitis infection model, suggesting this system may play an important role in protecting E. faecalis from clearance by the host immune response.